Choroidal Neovascularization - Pipeline Review, H1 2016 Summary Global Markets Direct's, ‘Choroidal Neovascularization - Pipeline Review, H1 2016', provides an overview of the Choroidal Neovascularization pipeline landscape. The report provides comprehensive information on the therapeutics under development for Choroidal Neovascularization, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Choroidal Neovascularization and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Choroidal Neovascularization - The report reviews pipeline therapeutics for Choroidal Neovascularization by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Choroidal Neovascularization therapeutics and enlists all their major and minor projects - The report assesses Choroidal Neovascularization therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Choroidal Neovascularization Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Choroidal Neovascularization - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Choroidal Neovascularization pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Choroidal Neovascularization Overview 7 Therapeutics Development 8 Pipeline Products for Choroidal Neovascularization - Overview 8 Pipeline Products for Choroidal Neovascularization - Comparative Analysis 9 Choroidal Neovascularization - Therapeutics under Development by Companies 10 Choroidal Neovascularization - Therapeutics under Investigation by Universities/Institutes 11 Choroidal Neovascularization - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Choroidal Neovascularization - Products under Development by Companies 15 Choroidal Neovascularization - Products under Investigation by Universities/Institutes 16 Choroidal Neovascularization - Companies Involved in Therapeutics Development 17 Affitech A/S 17 F. Hoffmann-La Roche Ltd. 18 Genentech, Inc. 19 Iconic Therapeutics, Inc. 20 Mabion SA 21 Navigen Pharmaceuticals, Inc. 22 Noxxon Pharma AG 23 Promedior, Inc. 24 Sanwa Kagaku Kenkyusho Co., Ltd. 25 Choroidal Neovascularization - Therapeutics Assessment 26 Assessment by Monotherapy Products 26 Assessment by Target 27 Assessment by Mechanism of Action 29 Assessment by Route of Administration 31 Assessment by Molecule Type 33 Drug Profiles 35 Antisense Oligonucleotides for Ophthalmology and Oncology - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 AP-202 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Doxarubicin Pegylated - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 hI-con1 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 MAb-30D8 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 NAV-2729 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Netrin-4 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 NM-9405 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 NOXD-20 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 PGN-635 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 PRM-167 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 ranibizumab - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 ranibizumab biosimilar - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 RG-7716 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 SK-1011 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 Small Molecule for Inflammation and Choroidal Neovascularization - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 Synthetic Peptides for Age Related Macular Degeneration and Choroidal Neovascularization - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 Synthetic Peptides to Target VEGF for Choroidal Neovascularization - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 Choroidal Neovascularization - Recent Pipeline Updates 62 Choroidal Neovascularization - Dormant Projects 68 Choroidal Neovascularization - Discontinued Products 69 Choroidal Neovascularization - Product Development Milestones 70 Featured News & Press Releases 70 Nov 26, 2013: NICE gives green light to ranibizumab for eye condition in final guidance 70 Jul 05, 2013: Novartis drug Lucentis approved in EU as first effective anti-VEGF treatment for myopic choroidal neovascularization 70 May 31, 2013: Novartis Receives Positive CHMP Opinion For Lucentis To Treat Myopic Choroidal Neovascularization Showing Vision Gains With Only Two Injections 71 Appendix 73 Methodology 73 Coverage 73 Secondary Research 73 Primary Research 73 Expert Panel Validation 73 Contact Us 73 Disclaimer 74
List of Tables
Number of Products under Development for Choroidal Neovascularization, H1 2016 8 Number of Products under Development for Choroidal Neovascularization - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Number of Products under Investigation by Universities/Institutes, H1 2016 11 Comparative Analysis by Late Stage Development, H1 2016 12 Comparative Analysis by Clinical Stage Development, H1 2016 13 Comparative Analysis by Early Stage Development, H1 2016 14 Products under Development by Companies, H1 2016 15 Products under Investigation by Universities/Institutes, H1 2016 16 Choroidal Neovascularization - Pipeline by Affitech A/S, H1 2016 17 Choroidal Neovascularization - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 18 Choroidal Neovascularization - Pipeline by Genentech, Inc., H1 2016 19 Choroidal Neovascularization - Pipeline by Iconic Therapeutics, Inc., H1 2016 20 Choroidal Neovascularization - Pipeline by Mabion SA, H1 2016 21 Choroidal Neovascularization - Pipeline by Navigen Pharmaceuticals, Inc., H1 2016 22 Choroidal Neovascularization - Pipeline by Noxxon Pharma AG, H1 2016 23 Choroidal Neovascularization - Pipeline by Promedior, Inc., H1 2016 24 Choroidal Neovascularization - Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H1 2016 25 Assessment by Monotherapy Products, H1 2016 26 Number of Products by Stage and Target, H1 2016 28 Number of Products by Stage and Mechanism of Action, H1 2016 30 Number of Products by Stage and Route of Administration, H1 2016 32 Number of Products by Stage and Molecule Type, H1 2016 34 Choroidal Neovascularization Therapeutics - Recent Pipeline Updates, H1 2016 62 Choroidal Neovascularization - Dormant Projects, H1 2016 68 Choroidal Neovascularization - Discontinued Products, H1 2016 69
List of Figures
Number of Products under Development for Choroidal Neovascularization, H1 2016 8 Number of Products under Development for Choroidal Neovascularization - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Comparative Analysis by Early Stage Products, H1 2016 14 Assessment by Monotherapy Products, H1 2016 26 Number of Products by Targets, H1 2016 27 Number of Products by Stage and Targets, H1 2016 27 Number of Products by Mechanism of Actions, H1 2016 29 Number of Products by Stage and Mechanism of Actions, H1 2016 29 Number of Products by Routes of Administration, H1 2016 31 Number of Products by Stage and Routes of Administration, H1 2016 31 Number of Products by Molecule Types, H1 2016 33 Number of Products by Stage and Molecule Types, H1 2016 33
Global fumaric acid market size is anticipated to be valued at USD 764.8 million by 2020, as per a new research report by Radiant Insights, Inc. Growing processed food demand coupled with RTD (ready-to-drink) beverages consumption is expected to drivRead More...
Global Biocides market size is likely to be valued at USD 11.9 billion by 2022; as per a new research report by Radiant Insights, Inc. Growth in water treatment process units particularly in China, Japan and India is likely to drive demand. IncreasinRead More...
Global engineering service outsourcing market size is likely to be valued at USD 415.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Rapid alignment of OEMs accompanied by increasing focus on efficient performance and reliabRead More...
Global CoQ10 market size was 687.2 tons in 2014 and is expected to reach 1,168 tons by 2020, growing at a CAGR of 9.2% from 2014 to 2020, according to a new study by Radiant Insights, Inc. Increasing scope in personal care applications is expected toRead More...
Global 3D scanning market is expected to be valued at USD 4,900.7 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing need for speedy and precise results with high efficiency is anticipated to drive the industry. 3DRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.